Ligand Pharmaceuticals (LGND) EBITDA Margin (2010 - 2026)
Ligand Pharmaceuticals (LGND) recorded EBITDA Margin of 26.39% in Q2 2026, down 9.24 percentage points from 35.62% a year earlier and down 23.08 percentage points from the prior quarter.
Ligand Pharmaceuticals (LGND) EBITDA Margin (2010 - 2026) Analysis & Trends
On a TTM basis, Ligand Pharmaceuticals' EBITDA Margin came in at 43.93% as of Jun 30, 2026, up 43.59 percentage points year-over-year; for FY2025, it was 27.89%, up 20.33 percentage points from FY2024.
- Annual EBITDA Margin has a five-year change of -10.74 percentage points (FY2020 to FY2025).
- Across earlier years, EBITDA Margin came in at 7.56% in FY2024 (-29.35 pp), 36.91% in FY2023 (+9.10 pp), 27.81% in FY2022 (-36.33 pp) and 64.14% in FY2021 (+25.50 pp).
- The Q2 2026 figure is the lowest quarterly EBITDA Margin since Q1 2025.
- On a year-over-year basis, EBITDA Margin rose in four of the last eight quarters, with an average year-over-year change of +12.37 percentage points.
- Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 110.01 percentage points in Q1 2026, against a drop of 107.96 percentage points in Q4 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at 49.46% (Q1 2026), 36.97% (Q4 2025) and 54.74% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,130.22 Bn | 1,098.81 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 613.62 Bn | 532.15 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 501.46 Bn | 474.57 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 366.84 Bn | 321.22 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 297.85 Bn | 261.84 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.66 Bn | 235.34 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 235.39 Bn | 190.79 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 190.66 Bn | 164.86 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 169.57 Bn | 116.22 Bn | 10.94 Bn | 39.16% |
| 10 | Ligand Pharmaceuticals | 6.17 Bn | 2.64 Bn | - | 27.68% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.68% |
| Mar 31, 2026 | 51.02% |
| Dec 31, 2025 | 37.91% |
| Sep 30, 2025 | 55.12% |
| Jun 30, 2025 | 35.89% |
| Mar 31, 2025 | -60.24% |
| Dec 31, 2024 | -1.96% |
| Sep 30, 2024 | 23.68% |
| Jun 30, 2024 | -24.44% |
| Mar 31, 2024 | 38.21% |
| Dec 31, 2023 | 20.07% |
| Sep 30, 2023 | 35.56% |
| Jun 30, 2023 | 28.73% |
| Mar 31, 2023 | 54.11% |
| Dec 31, 2022 | -17.60% |
| Sep 30, 2022 | 43.83% |
| Jun 30, 2022 | 44.09% |
| Mar 31, 2022 | 44.13% |
| Dec 31, 2021 | 96.96% |
| Sep 30, 2021 | 53.97% |
Ligand Pharmaceuticals EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=LGND&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "LGND", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=LGND&period=max&api_key=YOUR_API_KEY");
const data = await res.json();